Dissemination of Retinoblastoma Post-Enucleation: Histopathological Risk Factors Review
Downloads
Introduction: Examining the histopathological markers indicative of high risk in retinoblastoma is imperative for evaluating the potential for post-enucleation recurrence and metastatic spread. Purpose: This article seeks to elucidate diverse definitions of high-risk histopathological features in advanced retinoblastoma, which confer susceptibility to recurrence and metastasis following enucleation. Review: Reducing mortality rates associated with retinoblastoma poses a significant clinical challenge. It is well-established that post-laminar optic nerve invasion, extensive choroidal invasion, and scleral invasion are key features commonly observed in advanced retinoblastoma cases requiring enucleation. Conclusion: The presence of these features in advanced retinoblastoma necessitates adjunctive therapeutic interventions to reduce the risk of orbital recurrence or metastatic spread, thereby enhancing patient survival rates.
Global Retinoblastoma Study Group. The global retinoblastoma outcome study: A prospective, cluster-based analysis of 4064 patients from 149 countries. Lancet Glob Health 2022;10:1128–1140. https://doi.org/10.1016/S2214-109X(22)00250-9.
Shah A, Shrestha M, Shrestha SM, Khatri A, Shrestha PK. Pathologic risk factor in retinoblastoma: An institutional experience based on analysis of enucleated eyes. Nepal J Ophthalmol 2021;13:91–97. https://doi.org/10.3126/nepjoph.v13i1.31139.
Garin JPL, Sampor C, Grigorovski N, Ceciliano A, Fandiño A, Ossandon D, et al. How we approach conservative treatment of retinoblastoma in South America in the era of local ocular treatments: A consensus of the Grupo America Latina de Oncologia Pediatrica (GALOP). Pediatr Blood Cancer 2023;70:e30352. https://doi.org/10.1002/pbc.30352.
Aschero R, Francis JH, Ganiewich D, Gomez-Gonzalez S, Sampor C, Zugbi S, et al. Recurrent somatic chromosomal abnormalities in relapsed extraocular retinoblastoma. Cancers (Basel) 2021;13. https://doi.org/10.3390/cancers13040673.
Kaliki S, Shields CL, Cassoux N, Munier FL, Chantada G, Grossniklaus HE, et al. Defining high-risk retinoblastoma: A multicenter global survey. JAMA Ophthalmol 2022;140:30–36. https://doi.org/10.1001/jamaophthalmol.2021.4732.
Brennan RC, Qaddoumi I, Billups CA, Free TL, Haik BG, Rodriguez-Galindo C, et al. Comparison of high-risk histopathological features in eyes with primary or secondary enucleation for retinoblastoma. Br J Ophthalmol 2015;99:1366–1371. https://doi.org/10.1136/bjophthalmol-2014-306364.
Fabian ID, Stacey AW, Chowdhury T, Duncan C, Karaa EK, Scheimberg I, et al. High-risk histopathology features in primary and secondary enucleated international intraocular retinoblastoma classification group D eyes. Ophthalmology 2017;124:851–858. https://doi.org/10.1016/j.ophtha.2017.01.048.
Kaliki S, Gupta S, Ramappa G, Mohamed A, Mishra DK. High-risk retinoblastoma based on age at primary enucleation: A study of 616 eyes. Eye (Lond) 2020;34:1441–1448. https://doi.org/10.1038/s41433-019-0698-2.
Kaliki S, Jakati S, Vempuluru VS, Mallu A, Mishra DK. Retinoblastoma associated with orbital pseudocellulitis and high-risk retinoblastoma: A study of 32 eyes. Int Ophthalmol 2022;42:19–26. https://doi.org/10.1007/s10792-021-01993-w.
Laurent VE, Torbidoni AV, Sampor C, Ottaviani D, Vazquez V, Gabri MR, et al. Minimal disseminated disease in nonmetastatic retinoblastoma with high-risk pathologic features and association with disease-free survival. JAMA Ophthalmol 2016;134:1374–1379. https://doi.org/10.1001/jamaophthalmol.2016.4158.
Shaheen N, Inayat N, Bashir S, Sheikh UN, Bakar MA, Rehman P. Survival outcomes of unilateral retinoblastoma based on pathological risk stratification-experience at a tertiary care centre in Pakistan. Ecancermedicalscience 2022;16:1360. https://doi.org/10.3332/ecancer.2022.1360.
Yousef YA, Hajja Y, Nawaiseh I, Mehyar M, Sultan I, Deebajah R, et al. A histopathologic analysis of 50 eyes primarily enucleated for retinoblastoma in a tertiary cancer center in Jordan. Turk Patoloji Derg 2014;30:171–177. https://doi.org/10.5146/tjpath.2014.01260.
Chévez-Barrios P, Eagle RC, Krailo M, Piao J, Albert DM, Gao Y, et al. Study of unilateral retinoblastoma with and without histopathologic high-risk features and the role of adjuvant chemotherapy: A children’s oncology group study. J Clin Oncol 2019;37:2883–2891. https://doi.org/10.1200/JCO.18.01808.
Mendoza PR, Specht CS, Hubbard GB, Wells JR, Lynn MJ, Zhang Q, et al. Histopathologic grading of anaplasia in retinoblastoma. Am J Ophthalmol 2015;159:764–776. https://doi.org/10.1016/j.ajo.2014.12.014.
Mohammad M, Shehada R, Al-Nawaiseh I, Mehyar M, AlHussaini M, Jaradat I, et al. A comparison of high risk pathological features between primary and secondary enucleation for retinoblastoma. Eur J Ophthalmol 2023;33:2014–2023. https://doi.org/10.1177/11206721231155671.
Ye H, Du Y, Chen R, Luo X, Mao Y, Ai S, et al. The potential benefit of three vs. six cycles of carboplatin, etoposide, and vincristine in postenucleation high-risk patients with IRSS Stage I Retinoblastoma. Curr Eye Res 2016;41:1507–1512. https://doi.org/10.3109/02713683.2015.1130230.
Sari NM, Hadiputri R, Kuntorini MS, Agustina H, Mardianty F. High-risk histopathologic features of retinoblastoma treated at a tertiary hospital in West Java, Indonesia. Ocul Oncol Pathol 2021;7:353–360. https://doi.org/10.1159/000517100.
Zhao J, Feng Z, Leung G, Gallie BL. Retinoblastoma survival following primary enucleation by AJCC staging. Cancers (Basel) 2021;13. https://doi.org/10.3390/cancers13246240.
Shields CL, Shields JA, Baez KA, Cater J, De Potter P V. Choroidal invasion of retinoblastoma: Metastatic potential and clinical risk factors. Br J Ophthalmol 1993;77:544–548. https://doi.org/10.1136/bjo.77.9.544.
Chévez-Barrios P, Hurwitz MY, Louie K, Marcus KT, Holcombe VN, Schafer P, et al. Metastatic and nonmetastatic models of retinoblastoma. Am J Pathol 2000;157:1405–1412. https://doi.org/10.1016/S0002-9440(10)64653-6.
Kim JW, Kathpalia V, Dunkel IJ, Wong RK, Riedel E, Abramson DH. Orbital recurrence of retinoblastoma following enucleation. Br J Ophthalmol 2009;93:463–467. https://doi.org/10.1136/bjo.2008.138453.
Chong E-M, Coffee RE, Chintagumpala M, Hurwitz RL, Hurwitz MY, Chévez-Barrios P. Extensively necrotic retinoblastoma is associated with high-risk prognostic factors. Arch Pathol Lab Med 2006;130:1669–1672. https://doi.org/10.5858/2006-130-1669-ENRIAW.
Kashyap S, Sethi S, Meel R, Pushker N, Sen S, Bajaj MS, et al. A histopathologic analysis of eyes primarily enucleated for advanced intraocular retinoblastoma from a developing country. Arch Pathol Lab Med 2012;136:190–193. https://doi.org/10.5858/arpa.2010-0759-OA.
Kogachi K, Kim JW, Green S, Jubran R, Berry JL. Lurking below: Massive choroidal invasion under a calcified tumor after attempted conservative therapy for retinoblastoma. Ophthalmic Genet 2018;39:653–657. https://doi.org/10.1080/13816810.2018.1513535.
Munier FL. Classification and management of seeds in retinoblastoma Ellsworth Lecture Ghent August 24th 2013. Ophthalmic Genet 2014;35:193–207. https://doi.org/10.3109/13816810.2014.973045.
Jakati S, Kaliki S. Aqueous seeding in retinoblastoma: Classification and clinicopathologic correlation. Ophthalmol Retina 2022;6:421–428. https://doi.org/10.1016/j.oret.2021.12.013.
Copyright (c) 2024 Fitri Setyani Rokim
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Vision Science and Eye Health Journal by Universitas Airlangga is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
The journal allows the author to hold the copyright of the article without restrictions.
The journal allows the author(s) to retain publishing rights without restrictions.
The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution-Share-Alike (CC BY-SA).
The Creative Commons Attribution-Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violations.
